Phase I trial of temozolomide plus O(6)-benzylguanine 5-day regimen with recurrent malignant glioma

This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG). Both TMZ...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Quinn, Jennifer A., Jiang, Sara Xiaoyin, Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Rich, Jeremy N., Gururangan, Sridharan, Friedman, Allan H., Bigner, Darell D., Sampson, John H., McLendon, Roger E., Herndon, James E., Walker, Amy, Friedman, Henry S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Duke University Press 2009
Aiheet:
Clinical Investigations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2765345/
https://ncbi.nlm.nih.gov/pubmed/19289491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2009-007
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia